Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation

It is not understood if dabigatran or rivaroxaban are superior to antiplatelet agents (AA) for safety outcomes in Asians with non-valvular atrial fibrillation (NVAF). In this study we evaluated the bleeding risk of dabigatran, rivaroxaban, warfarin and AA in Asians with NVAF. This national retrospec...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Chan, Yi-Hsin, Yeh, Yung-Hsin, Tu, Hui-Tzu, Kuo, Chi-Tai, Chang, Shang-Hung, Wu, Lung-Sheng, Lee, Hsin-Fu, See, Lai-Chu
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2017
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5716776/
https://ncbi.nlm.nih.gov/pubmed/29228736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22026
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk